EQ

Equillium, Inc.

0.73 USD
-0.05 (-6.58%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Equillium, Inc. stock is down -52.35% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About Equillium, Inc.

Equillium, Inc. develops and sells products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6.

  • HC Wainwright & Co.
    Wed Jun 5, 07:17
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 17, 10:08
    buy
    confirm